• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

TraffikGene gets €2.5M from the European Innovation Council to bring its technology to market

Bioengineer by Bioengineer
February 23, 2023
in Science News
Reading Time: 2 mins read
0
TraffikGene
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The European Innovation Council (EIC) announced on February 8 the beneficiaries of EIC Transition projects, in the context of the challenge “New RNA-based therapies and diagnostics”, which seeks to advance the transfer of innovative technologies for future commercialization.  From the 181 submitted proposals, only 34 were funded, including TraffikGene, which will now receive €2.5M over a period of 3 years.

TraffikGene

Credit: CiQUS – USC

The European Innovation Council (EIC) announced on February 8 the beneficiaries of EIC Transition projects, in the context of the challenge “New RNA-based therapies and diagnostics”, which seeks to advance the transfer of innovative technologies for future commercialization.  From the 181 submitted proposals, only 34 were funded, including TraffikGene, which will now receive €2.5M over a period of 3 years.

The project led by Prof. Javier Montenegro focuses on the development of a peptide-based technology to create vehicles that facilitate the efficient delivery of nucleic acids and ribonucleoproteins with potential therapeutic application. “Our vehicles are designed to bring these nucleic acids to their site of action in an efficient, non-toxic and selective manner. In this way we overcome one of the main challenges in the development of new nucleic acid-based drugs,” explains Prof. Montenegro, principal investigator at the Singular Center for Research in Biological Chemistry and Molecular Materials (CIQUS) of the University of Santiago de Compostela (USC).

TraffikGene provides a versatile technology, which can adapt to all types of nucleic acids, such as messenger RNA (mRNA), interfering RNA (RNAi) or even enable gene editing tasks with ribonucleoproteins through the CRISPR/Cas system. The vehicles for RNA drugs developed by TraffikGene are biodegradable and therefore have very little toxicity. Synthetic simplicity, ease of formulation with RNA and a high delivery efficiency make this technology very attractive for therapeutic application. The new EIC support will allow the team behind this project to focus on the development of messenger RNA (mRNA) therapies for applications in cancer immunotherapy and explore other possible therapeutic alternatives with different nucleic acids. In addition, the TraffikGene team will seek collaboration with academia and industry to accelerate the validation and transfer of the technology: “We want to develop our own pipeline of RNA therapeutic products and also use our technology to support academic groups or industrial partners with potential therapeutic RNAs in need of an efficient and selective vehicle,” explains Dr. Mark Mayhew, strategic advisor to TraffikGene.

“We hope that, within three years the technology, will be ready to make the leap to clinical phases and thus be able to reach patients,” says Dr. Marisa Juanes, in charge of the synthetic development of RNA carriers  and their biological evaluation. The project team is completed by Dr. Irene Lostalé, responsible for methodological design and biological protocols, and Dr. Alberto Fuertes, responsible for project operations. TraffikGene, which was awarded the Best Business Idea by the Regional Biotech Cluster of Galicia (BIOGA), has also been recognized by the Proof  of Concept grant by Spanish AEI, from the European Research Council (ERC-Proof of Concept) and by the Galician Innovation Agency (GAIN) through the Ignicia project.



Share12Tweet8Share2ShareShareShare2

Related Posts

Movement Skills Boost Executive Function in Autistic Kids

October 2, 2025

Mayo Clinic Secures Up to $40 Million from ARPA-H to Advance Groundbreaking Air Safety Research

October 2, 2025

Atlas Reveals Testicular Aging Across Species

October 2, 2025

Early Onset of Neuroinflammation Observed in Individuals with Down Syndrome

October 2, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    92 shares
    Share 37 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    82 shares
    Share 33 Tweet 21
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Movement Skills Boost Executive Function in Autistic Kids

Mayo Clinic Secures Up to $40 Million from ARPA-H to Advance Groundbreaking Air Safety Research

Atlas Reveals Testicular Aging Across Species

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.